Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts.
OBJECTIVE
The purpose of this study was to assess the therapeutic and toxicological effects of cesium chloride (CsCl) administration in mice bearing prostate cancer tumors.


METHODS
Three CsCl dose titration studies were completed in tumor-bearing and non-tumor-bearing athymic nude mice. All mice were administered either vehicle (controls), 150, 300, 600, 800, 1,000, or 1,200 mg/kg of CsCl once daily by oral gavage for 30 consecutive days. Body mass was measured daily, food and water consumption were measured every 2 days, and tumor volume was measured twice weekly. Histopathological analysis was conducted on tissues collected from each of the studies. Serum AST/ALT and creatinine were also measured.


RESULTS
Administration of 800-1,200 mg/kg CsCl reduced PC-3 tumor growth but had no effect on LNCaP tumors. Administration of 800-1,200 mg/kg CsCl also resulted in increased water consumption, bladder crystal development, and higher prevalence of cardiac fibrin clots. An observed loss in body mass was dependent on the xenograft type and concentration of CsCl administered. CsCl did not affect serum AST/ALT and creatinine levels.


CONCLUSIONS
CsCl may have a therapeutic effect against prostate cancer, but one cannot overlook the acute toxicities also described.
Low
Jonathan C
JC
Urologic Sciences, The Prostate Center at Vancouver General Hospital, 2660 Oak Street, Vancouver, BC, Canada V6H 3Z4. Emma.Guns@vch.ca
Wasan
Kishor M
KM
Fazli
Ladan
L
Eberding
Andy
A
Adomat
Hans
H
Guns
Emma S
ES
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D001835:Body Weight / Q000187:drug effects; D045744:Cell Line, Tumor; D002586:Cesium / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D002712:Chlorides / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D003460:Crystallization; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005337:Fibrin / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008111:Liver Function Tests; D008297:Male; D051379:Mice; D008819:Mice, Nude; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011897:Random Allocation; D013894:Thirst / Q000187:drug effects; D013927:Thrombosis / Q000139:chemically induced; D001743:Urinary Bladder / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D002712:Chlorides; D002586:Cesium; D005337:Fibrin; D017430:Prostate-Specific Antigen; C028019:cesium chloride